AT 1015
Latest Information Update: 05 Sep 2002
At a glance
- Originator Ajinomoto
- Class Vascular disorder therapies
- Mechanism of Action Platelet aggregation inhibitors; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies; Intermittent claudication; Thrombosis
Most Recent Events
- 05 Sep 2002 Discontinued - Phase-I for Diabetic neuropathies in Japan (unspecified route)
- 05 Sep 2002 Discontinued - Phase-I for Thrombosis in Japan (unspecified route)
- 05 Sep 2002 Discontinued - Phase-II for Intermittent claudication in Europe (unspecified route)